 "Claris get nod for Tobramycin injection is the US")
Claris Lifesciences rallied 13% to Rs 246 in early morning trade on the BSE after the company said that it has received the Abbreviated New Drug Application (ANDA) approval for Tobramycin Injection USP, 80mg/2mL and 1,200mg/30mL multiple dose vials, in the US.
“Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract,” Claris Lifesciences said in a press release.
The estimated market size in the US is $6 million, as the product is currently in shortage list of the US dug regulator, US Food and Drug Administration (USFDA), it added.
Claris expects more product approvals during the year, which will allow it to continue its growth in the US market.
At 09:21 AM, the stock was up 9% at Rs 237 on the BSE. Around 88,000 shares changed hands on the counter against an average sub 50,000 shares that were traded daily in past two weeks on the BSE.
“Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract,” Claris Lifesciences said in a press release.
The estimated market size in the US is $6 million, as the product is currently in shortage list of the US dug regulator, US Food and Drug Administration (USFDA), it added.
Claris expects more product approvals during the year, which will allow it to continue its growth in the US market.
At 09:21 AM, the stock was up 9% at Rs 237 on the BSE. Around 88,000 shares changed hands on the counter against an average sub 50,000 shares that were traded daily in past two weeks on the BSE.
